Capillary electrophoresis of urinary prostate glycoproteins assists in the diagnosis of prostate cancer. Issue 7 (20th December 2013)

• Record Type: Journal Article
• Authors: Vermassen, Tijl; Van, Charles; Vanderschaeghe, Dieter; Maenhout, Thomas; Lumen, Nicolaas; Callewaert, Nico; Hoebeke, Piet; Van Belle, Simon; Rottey, Sylvie; Delanghe, Joris; Phillips, Terry M.
• Is Part Of: Electrophoresis. Volume 35:Issue 7(2014:Apr.)
• Page Start: 1017
• Page End: 1024
• Publication Date: 2013-12-20
• Subjects: Electrophoresis -- Periodicals; Electrophoresis -- Periodicals; 541.372
• DOI: 10.1002/elps.201300332
• Languages: English
• ISSNs: 0173-0835

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>Prostate marker assays are widely used for detection of prostate cancer (PCa) but are associated with considerable sensitivity and specificity problems. Therefore, we investigated prostatic protein glycosylation profiles as a potential biomarker. We determined the urinary asparagine‐linked glycan (<italic>N</italic>‐glycan) profile of prostatic proteins of healthy volunteers (<italic>n</italic> = 25), patients with benign prostate hyperplasia (BPH; <italic>n</italic> = 62) and newly diagnosed PCa patients (<italic>n</italic> = 42) using DNA‐sequencer‐assisted fluorophore‐assisted carbohydrate electrophoresis. Through squeezing of the prostate, a sufficient amount of prostatic proteins was obtained for direct structural analyses of <italic>N</italic>‐glycan structures. <italic>N</italic>‐glycans of PCa compared to BPH were characterized by a significant decrease in triantennary structures (<italic>p</italic> = 0.047) and overall fucosylation (<italic>p</italic> = 0.026). Prostate‐specific antigen (PSA) and the urinary glycoprofile marker showed comparable overall receiver operating characteristic curve analysis as well as in the diagnostic gray zone with serum PSA values between 4 and 10 μg/L. However, when combining PSA and the urinary glycoprofile marker, the latter gave an additive diagnostic value to serum PSA (<italic>p</italic> ≤ 0.001). In conclusion, <italic>N</italic>‐glycosylation profiling demonstrated differences between BPH and PCa. These changes could lead to the discovery of a new biomarker for PCa.</p> </abstract>